LONDON — The German biotechnology company CureVac says it has withdrawn its application for the approval of its coronavirus vaccine from the European Medicines Agency and will focus on making next-generation messenger RNA vaccines.
In a statement on Tuesday, CureVac says recent communications with the EU drug regulator suggested its COVID-19 vaccine might only be authorized in mid-2022. Earlier this year, the company described its initial vaccine results as “sobering,” after data suggested the shot was only about 47% effective.
CureVac says it will instead prioritize the development of second-generation mRNA vaccines with its partner GlaxoSmithKline and expects to be in “late-stage clinical development” by the middle of next year.
The EMA confirmed Tuesday it had ended the accelerated evaluation of the CureVac vaccine, a process started in February. COVAX, the U.N.-backed effort to share vaccines globally, had been waiting for possible doses from CureVac, which received funding from one of the COVAX partners.